{"component": "clause", "props": {"groups": [{"samples": [{"hash": "53bJ5lendfA", "uri": "/contracts/53bJ5lendfA#continued-development", "label": "License Agreement (Fusion Pharmaceuticals Inc.)", "score": 31.4257357974, "published": true}, {"hash": "kzV10tIAs6", "uri": "/contracts/kzV10tIAs6#continued-development", "label": "License Agreement (Fusion Pharmaceuticals Inc.)", "score": 31.379192334, "published": true}], "size": 2, "snippet": "At ImmunoGen\u2019s request and expense, Licensee shall continue on-going Development for a mutually agreed-upon period following terminating of this Agreement, which period shall not be less than [***] unless otherwise agreed to by the Parties. For avoidance of doubt, if ImmunoGen chooses not to continue a Clinical Trial initiated by Licensee, Licensee shall be solely responsible for the cost of winding down such trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority.", "snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [36, 50]}, {"key": "mutually-agreed", "type": "clause", "offset": [87, 102]}, {"key": "this-agreement", "type": "clause", "offset": [140, 154]}, {"key": "by-the-parties", "type": "clause", "offset": [225, 239]}, {"key": "for-avoidance-of-doubt", "type": "clause", "offset": [241, 263]}, {"key": "clinical-trial", "type": "clause", "offset": [304, 318]}, {"key": "by-licensee", "type": "clause", "offset": [329, 340]}, {"key": "responsible-for", "type": "clause", "offset": [367, 382]}, {"key": "cost-of", "type": "definition", "offset": [387, 394]}, {"key": "winding-down", "type": "clause", "offset": [395, 407]}, {"key": "compliance-with", "type": "definition", "offset": [430, 445]}, {"key": "other-requirements", "type": "clause", "offset": [461, 479]}, {"key": "applicable-regulatory-authority", "type": "clause", "offset": [494, 525]}], "hash": "2ec3d75b3a626bb0dace77c306428ae1", "id": 7}, {"samples": [{"hash": "ghJEjmfzDVA", "uri": "/contracts/ghJEjmfzDVA#continued-development", "label": "Global Access and Price Commitment Agreement (Icosavax, Inc.)", "score": 32.5126625599, "published": true}, {"hash": "6DgzNj95vfU", "uri": "/contracts/6DgzNj95vfU#continued-development", "label": "Global Access and Price Commitment Agreement (Icosavax, Inc.)", "score": 32.3648186174, "published": true}], "size": 2, "snippet": "In the event of successful completion of the Phase 1 study of the Covid Vaccine as described in the Project, and the Foundation has made all payments to Icosavax in accordance with the terms of the Grant Agreement, Icosavax will take reasonable steps to obtain additional funding for completing the activities necessary to further develop the Covid Vaccine beyond the Phase 1 study. Within [***] of the [***], Icosavax will have received or will have a [***] to further develop, manufacture, and/or distribute the Covid Vaccine. If Icosavax [***] and continues the development and commercialization of the Covid Vaccine, the following terms apply:", "snippet_links": [{"key": "in-the-event-of", "type": "definition", "offset": [0, 15]}, {"key": "phase-1-study", "type": "definition", "offset": [45, 58]}, {"key": "the-project", "type": "clause", "offset": [96, 107]}, {"key": "the-foundation", "type": "clause", "offset": [113, 127]}, {"key": "payments-to", "type": "definition", "offset": [141, 152]}, {"key": "in-accordance-with", "type": "definition", "offset": [162, 180]}, {"key": "terms-of-the-grant-agreement", "type": "clause", "offset": [185, 213]}, {"key": "reasonable-steps", "type": "definition", "offset": [234, 250]}, {"key": "additional-funding", "type": "definition", "offset": [261, 279]}, {"key": "the-activities", "type": "clause", "offset": [295, 309]}, {"key": "distribute-the", "type": "clause", "offset": [499, 513]}, {"key": "development-and-commercialization", "type": "clause", "offset": [565, 598]}], "hash": "e30bf9855c72baa35a0354bdcd2ce946", "id": 5}, {"samples": [{"hash": "amzt7Rb2Jqh", "uri": "/contracts/amzt7Rb2Jqh#continued-development", "label": "License Agreement (Iterum Therapeutics LTD)", "score": 29.3285420945, "published": true}, {"hash": "56ihTe7887k", "uri": "/contracts/56ihTe7887k#continued-development", "label": "License Agreement (Iterum Therapeutics LTD)", "score": 29.0876112252, "published": true}, {"hash": "912WpLZCwsj", "uri": "/contracts/912WpLZCwsj#continued-development", "label": "License Agreement", "score": 26.1704312115, "published": true}], "size": 3, "snippet": "At Pfizer\u2019s request and expense, Iterum shall continue on-going Development for a mutually agreed-upon period following termination of this Agreement, which period shall be at least [ * ] but not be less than [ * ] unless otherwise agreed to by the Parties. For avoidance of doubt, if Pfizer chooses not to continue a Clinical Trial initiated by Iterum, Iterum shall be solely responsible for the cost of winding down such trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority.", "snippet_links": [{"key": "mutually-agreed", "type": "clause", "offset": [82, 97]}, {"key": "following-termination-of-this-agreement", "type": "clause", "offset": [110, 149]}, {"key": "by-the-parties", "type": "clause", "offset": [242, 256]}, {"key": "for-avoidance-of-doubt", "type": "clause", "offset": [258, 280]}, {"key": "clinical-trial", "type": "clause", "offset": [318, 332]}, {"key": "responsible-for", "type": "clause", "offset": [377, 392]}, {"key": "cost-of", "type": "definition", "offset": [397, 404]}, {"key": "winding-down", "type": "clause", "offset": [405, 417]}, {"key": "compliance-with", "type": "definition", "offset": [440, 455]}, {"key": "other-requirements", "type": "clause", "offset": [471, 489]}, {"key": "applicable-regulatory-authority", "type": "clause", "offset": [504, 535]}], "hash": "d1e14f1e6a58ce4ed980b24a2c5a005a", "id": 1}, {"samples": [{"hash": "hf6JEPiwJnT", "uri": "/contracts/hf6JEPiwJnT#continued-development", "label": "Development Agreement (Anthra Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "dbdkUO2Tsx8", "uri": "/contracts/dbdkUO2Tsx8#continued-development", "label": "Development Agreement (Anthra Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "4ksYCrPxbvZ", "uri": "/contracts/4ksYCrPxbvZ#continued-development", "label": "Development Agreement (Anthra Pharmaceuticals Inc)", "score": 18.0, "published": true}], "size": 3, "snippet": "In the event that Anthra reasonably determines at any time that the NDA for an indication for the Product is unlikely to be approved by the FDA, then it shall so notify Medeva, whereupon Anthra shall have no further obligation pursuant to this Article II to conduct any Development Activities with respect to such indication for the Product. Upon receipt of such notice, Medeva shall elect, in its sole discretion, either to terminate this Agreement with respect to such indication for the Product, or to continue (or contract for a third party to continue) such Development Activities at the sole expense of Medeva. Medeva shall notify Anthra of such election within ninety (90) days after the receipt of the notice referred to *** CONFIDENTIAL TREATMENT REQUESTED.", "snippet_links": [{"key": "in-the-event", "type": "clause", "offset": [0, 12]}, {"key": "at-any-time", "type": "clause", "offset": [47, 58]}, {"key": "the-product", "type": "clause", "offset": [94, 105]}, {"key": "approved-by", "type": "definition", "offset": [124, 135]}, {"key": "the-fda", "type": "clause", "offset": [136, 143]}, {"key": "no-further-obligation", "type": "clause", "offset": [205, 226]}, {"key": "pursuant-to", "type": "definition", "offset": [227, 238]}, {"key": "article-ii", "type": "definition", "offset": [244, 254]}, {"key": "development-activities", "type": "clause", "offset": [270, 292]}, {"key": "with-respect-to", "type": "clause", "offset": [293, 308]}, {"key": "upon-receipt-of", "type": "definition", "offset": [342, 357]}, {"key": "sole-discretion", "type": "clause", "offset": [398, 413]}, {"key": "terminate-this-agreement", "type": "clause", "offset": [425, 449]}, {"key": "contract-for", "type": "definition", "offset": [518, 530]}, {"key": "a-third-party", "type": "clause", "offset": [531, 544]}, {"key": "sole-expense", "type": "definition", "offset": [593, 605]}, {"key": "days-after", "type": "definition", "offset": [680, 690]}, {"key": "the-notice", "type": "clause", "offset": [706, 716]}, {"key": "confidential-treatment-requested", "type": "definition", "offset": [733, 765]}], "hash": "a49dece2b0882d041ea628b77f8aa661", "id": 2}, {"samples": [{"hash": "kIRWB8yXQzR", "uri": "/contracts/kIRWB8yXQzR#continued-development", "label": "License Agreement (SpringWorks Therapeutics, Inc.)", "score": 30.620807666, "published": true}, {"hash": "fusUxvTFrUA", "uri": "/contracts/fusUxvTFrUA#continued-development", "label": "License Agreement", "score": 24.1704312115, "published": true}], "size": 3, "snippet": "At Pfizer\u2019s request, Licensee shall continue on-going Development of the Products for a mutually agreed-upon period following termination of this Agreement, which period shall not be less than three (3) months unless otherwise agreed to by the Parties; provided, however, that if Pfizer chooses not to continue a Clinical Trial initiated by Licensee or if, for the safety of any subject, any Clinical Trial with respect to a Product should not be continued, Licensee shall be solely responsible for the cost of winding down such trial, including any costs arising from compliance with any ethical or other requirements imposed by an applicable Regulatory Authority.", "snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [21, 35]}, {"key": "development-of-the-products", "type": "clause", "offset": [54, 81]}, {"key": "mutually-agreed", "type": "clause", "offset": [88, 103]}, {"key": "following-termination-of-this-agreement", "type": "clause", "offset": [116, 155]}, {"key": "by-the-parties", "type": "clause", "offset": [237, 251]}, {"key": "clinical-trial", "type": "clause", "offset": [313, 327]}, {"key": "by-licensee", "type": "clause", "offset": [338, 349]}, {"key": "the-safety", "type": "clause", "offset": [361, 371]}, {"key": "with-respect-to", "type": "clause", "offset": [407, 422]}, {"key": "responsible-for", "type": "clause", "offset": [483, 498]}, {"key": "cost-of", "type": "definition", "offset": [503, 510]}, {"key": "winding-down", "type": "clause", "offset": [511, 523]}, {"key": "compliance-with", "type": "definition", "offset": [569, 584]}, {"key": "other-requirements", "type": "clause", "offset": [600, 618]}, {"key": "applicable-regulatory-authority", "type": "clause", "offset": [633, 664]}], "hash": "7d74bff646f6b4f8196a6b77ab5ebefe", "id": 3}, {"samples": [{"hash": "awRCUKtDqUR", "uri": "/contracts/awRCUKtDqUR#continued-development", "label": "License Agreement (JATT Acquisition Corp)", "score": 34.1279945243, "published": true}, {"hash": "cZViBCaw3kM", "uri": "/contracts/cZViBCaw3kM#continued-development", "label": "License Agreement (JATT Acquisition Corp)", "score": 33.6379192334, "published": true}], "size": 3, "snippet": "At Pfizer\u2019s request and expense, Licensee shall continue on-going Development for a mutually agreed-upon period following terminating of this Agreement, which period shall not be less than [***] unless otherwise agreed to by the Parties. For avoidance of doubt, if Pfizer chooses not to continue a Clinical Trial initiated by Licensee, Licensee shall be solely responsible for the cost of winding down such trial, including compliance with any ethical or other requirements imposed by an applicable Regulatory Authority.", "snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [33, 47]}, {"key": "mutually-agreed", "type": "clause", "offset": [84, 99]}, {"key": "this-agreement", "type": "clause", "offset": [137, 151]}, {"key": "by-the-parties", "type": "clause", "offset": [222, 236]}, {"key": "for-avoidance-of-doubt", "type": "clause", "offset": [238, 260]}, {"key": "clinical-trial", "type": "clause", "offset": [298, 312]}, {"key": "by-licensee", "type": "clause", "offset": [323, 334]}, {"key": "responsible-for", "type": "clause", "offset": [361, 376]}, {"key": "cost-of", "type": "definition", "offset": [381, 388]}, {"key": "winding-down", "type": "clause", "offset": [389, 401]}, {"key": "compliance-with", "type": "definition", "offset": [424, 439]}, {"key": "other-requirements", "type": "clause", "offset": [455, 473]}, {"key": "applicable-regulatory-authority", "type": "clause", "offset": [488, 519]}], "hash": "9e3ec6399c662be40c01a0960c67fa10", "id": 4}, {"samples": [{"hash": "7SPi7EdliTz", "uri": "/contracts/7SPi7EdliTz#continued-development", "label": "Mastercard Developers Evaluation Agreement", "score": 26.8028747433, "published": true}, {"hash": "bIlQrbRhQbs", "uri": "/contracts/bIlQrbRhQbs#continued-development", "label": "Evaluation Agreement", "score": 26.3497604381, "published": true}], "size": 2, "snippet": "In order to facilitate continued development of, and integration with, each Service API and Web Service by You and others, (a) You hereby grant to Mastercard, licensees of Mastercard Developers Materials, and users of each Service API and Web Service a limited non-exclusive, royalty-free, irrevocable, worldwide license under any patent claims arising from Your development of or otherwise owned or licensable by You and covering Licensed Implementations to use, make, have made, sell, offer to sell, and import the products, services, and solutions that implement a Service API or that integrate with a Web Service; and (b) You hereby grant to Mastercard a perpetual, irrevocable, nonexclusive, transferable, royalty-free, fully paid-up, worldwide license with the right to grant sublicenses to use and exploit in any manner and without any restrictions, any suggestions that You provide to Mastercard regarding a Service API, a Web Service, or the Mastercard Developers Materials, including suggestions for improvements and corrections. In addition, Mastercard is not obligated to maintain the confidentiality of any information made available by You to Mastercard under this Agreement.", "snippet_links": [{"key": "in-order-to", "type": "clause", "offset": [0, 11]}, {"key": "development-of", "type": "clause", "offset": [33, 47]}, {"key": "service-api", "type": "definition", "offset": [76, 87]}, {"key": "web-service", "type": "clause", "offset": [92, 103]}, {"key": "a-limited", "type": "clause", "offset": [251, 260]}, {"key": "worldwide-license", "type": "clause", "offset": [303, 320]}, {"key": "patent-claims", "type": "definition", "offset": [331, 344]}, {"key": "offer-to-sell", "type": "clause", "offset": [487, 500]}, {"key": "the-products", "type": "clause", "offset": [513, 525]}, {"key": "fully-paid", "type": "clause", "offset": [725, 735]}, {"key": "the-right-to-grant-sublicenses", "type": "clause", "offset": [763, 793]}, {"key": "in-addition", "type": "clause", "offset": [1040, 1051]}, {"key": "to-maintain", "type": "clause", "offset": [1081, 1092]}, {"key": "available-by", "type": "definition", "offset": [1137, 1149]}, {"key": "this-agreement", "type": "clause", "offset": [1174, 1188]}], "hash": "2c96c9a45c391055fd78d8b6d973a434", "id": 6}, {"samples": [{"hash": "caje3fw4O72", "uri": "/contracts/caje3fw4O72#continued-development", "label": "Collaboration and Exclusive License Agreement (Transgenomic Inc)", "score": 21.0, "published": true}], "size": 2, "snippet": "Within thirty (30) days following the execution of this Agreement, Transgenomic shall create a bank account funded with the amount of One Hundred Fifty Thousand Dollars ($150,000), said account to be owned by Transgenomic, and which funds will be used by Power3, with prior agreement by Transgenomic, to fund Power3\u2019s clinical validation activities of the Neurodegenerative Diagnostic Tests; provided that the availability of such funds to Power3 shall be governed by the terms and conditions set forth in the Disbursement Control Agreement attached hereto as Exhibit D. Clinical validation of the Neurodegenerative Diagnostic Tests shall be the responsibility of Power3 until such time, if any, as Transgenomic shall assume some or all of the future responsibility for clinical validation of the Neurodegenerative Diagnostic Tests pursuant to Section 8.2. Power3 shall use commercially reasonable efforts for said development and shall keep Transgenomic informed about its progress in regular reports. Power3 shall disclose to Transgenomic the available technical and clinical performance data of the then-current version of its tests on regular basis, but in no event less often than monthly.\n8.1.1 During the period of continued development of the Neurodegenerative Diagnostic Tests by Power3, Power3 shall:\n(a) prepare an Operating Plan and Budget for the clinical validation activities;\n(b) provide suitable laboratory facilities, equipment and personnel for the work to be done in carrying out the clinical validation activities;\n(c) coordinate and obtain the approval of Transgenomic prior to the publication of research results obtained from such continued development activities;\n(d) discuss with Transgenomic whether a license(s) need be obtained from any Third Person(s) in order to make, use or sell the Licensed Product;\n(e) determine, subject to the approval of Transgenomic, the priority of assays to be commercialized;\n(f) discuss the patent/intellectual property strategy and implementation plan for development and commercialization;\n(g) furnish Transgenomic with summary reports within fifteen (15) days after the end of each calendar quarter, describing its progress under the Operating Plan and Budget; and\n(h) prepare and furnish to Transgenomic comprehensive written reports within thirty (30) days after the end of each calendar quarter describing in detail the work accomplished by Power3 during such quarter and evaluating the results of such work.\n(i) Discuss the plan and timing of development by Transgenomic of next-generation high-throughput immunoassays and platforms, and the plan, timing and budget for the supporting role to be taken by Power3 in these efforts.\n8.1.2 Power3 shall keep complete and accurate records of its expenditures under the Operating Plan and Budget. Transgenomic shall have the right, at its own expense, to appoint an independent certified public accountant to examine such records, during regular business hours at the place or places where such records are customarily kept, upon reasonable notice from Transgenomic, to the extent reasonably necessary to verify the accuracy of the expenditures and required reports. Transgenomic agrees to hold in confidence all information concerning such expenditures, other than their total amounts, and all information learned in the course of any audit or inspection, except to the extent that it is necessary for Transgenomic to reveal the information in order to enforce any rights it may have pursuant to this Agreement or if disclosure is required by law. Failure by Transgenomic to request verification of any expenditures within two years after such expenditure has been made shall be considered acceptance of the accuracy of such expenditure, and Power3 shall have no obligation to maintain any records pertaining to such report or statement beyond the two-year period.", "snippet_links": [{"key": "within-thirty", "type": "clause", "offset": [0, 13]}, {"key": "execution-of-this-agreement", "type": "clause", "offset": [38, 65]}, {"key": "bank-account", "type": "clause", "offset": [95, 107]}, {"key": "owned-by", "type": "definition", "offset": [200, 208]}, {"key": "prior-agreement", "type": "definition", "offset": [268, 283]}, {"key": "to-fund", "type": "definition", "offset": [301, 308]}, {"key": "activities-of-the", "type": "clause", "offset": [338, 355]}, {"key": "diagnostic-tests", "type": "definition", "offset": [374, 390]}, {"key": "provided-that", "type": "clause", "offset": [392, 405]}, {"key": "availability-of", "type": "clause", "offset": [410, 425]}, {"key": "the-terms-and-conditions", "type": "definition", "offset": [468, 492]}, {"key": "control-agreement", "type": "definition", "offset": [523, 540]}, {"key": "attached-hereto-as-exhibit", "type": "definition", "offset": [541, 567]}, {"key": "responsibility-of", "type": "clause", "offset": [646, 663]}, {"key": "the-future", "type": "clause", "offset": [740, 750]}, {"key": "responsibility-for", "type": "clause", "offset": [751, 769]}, {"key": "section-82", "type": "clause", "offset": [844, 855]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [870, 905]}, {"key": "regular-reports", "type": "clause", "offset": [986, 1001]}, {"key": "technical-and", "type": "clause", "offset": [1055, 1068]}, {"key": "performance-data", "type": "definition", "offset": [1078, 1094]}, {"key": "current-version", "type": "clause", "offset": [1107, 1122]}, {"key": "regular-basis", "type": "definition", "offset": [1139, 1152]}, {"key": "in-no-event", "type": "clause", "offset": [1158, 1169]}, {"key": "period-of", "type": "definition", "offset": [1212, 1221]}, {"key": "development-of-the", "type": "clause", "offset": [1232, 1250]}, {"key": "operating-plan-and-budget", "type": "definition", "offset": [1326, 1351]}, {"key": "laboratory-facilities", "type": "clause", "offset": [1413, 1434]}, {"key": "equipment-and-personnel", "type": "clause", "offset": [1436, 1459]}, {"key": "work-to-be-done", "type": "clause", "offset": [1468, 1483]}, {"key": "approval-of", "type": "clause", "offset": [1566, 1577]}, {"key": "prior-to-the", "type": "clause", "offset": [1591, 1603]}, {"key": "publication-of-research-results", "type": "clause", "offset": [1604, 1635]}, {"key": "development-activities", "type": "clause", "offset": [1665, 1687]}, {"key": "in-order-to", "type": "clause", "offset": [1782, 1793]}, {"key": "licensed-product", "type": "clause", "offset": [1816, 1832]}, {"key": "subject-to-the-approval", "type": "definition", "offset": [1849, 1872]}, {"key": "the-patent", "type": "definition", "offset": [1947, 1957]}, {"key": "intellectual-property-strategy", "type": "clause", "offset": [1958, 1988]}, {"key": "implementation-plan", "type": "clause", "offset": [1993, 2012]}, {"key": "development-and-commercialization", "type": "clause", "offset": [2017, 2050]}, {"key": "summary-reports", "type": "clause", "offset": [2082, 2097]}, {"key": "days-after", "type": "definition", "offset": [2118, 2128]}, {"key": "calendar-quarter", "type": "clause", "offset": [2145, 2161]}, {"key": "furnish-to", "type": "clause", "offset": [2244, 2254]}, {"key": "written-reports", "type": "clause", "offset": [2282, 2297]}, {"key": "in-detail", "type": "clause", "offset": [2372, 2381]}, {"key": "the-plan", "type": "clause", "offset": [2487, 2495]}, {"key": "timing-of-development", "type": "clause", "offset": [2500, 2521]}, {"key": "complete-and-accurate-records", "type": "clause", "offset": [2721, 2750]}, {"key": "the-right", "type": "clause", "offset": [2832, 2841]}, {"key": "independent-certified-public-accountant", "type": "definition", "offset": [2877, 2916]}, {"key": "regular-business-hours", "type": "definition", "offset": [2949, 2971]}, {"key": "upon-reasonable-notice", "type": "clause", "offset": [3036, 3058]}, {"key": "reasonably-necessary", "type": "clause", "offset": [3092, 3112]}, {"key": "to-verify", "type": "definition", "offset": [3113, 3122]}, {"key": "accuracy-of-the", "type": "clause", "offset": [3127, 3142]}, {"key": "required-reports", "type": "clause", "offset": [3160, 3176]}, {"key": "agrees-to", "type": "clause", "offset": [3191, 3200]}, {"key": "in-confidence", "type": "clause", "offset": [3206, 3219]}, {"key": "information-concerning", "type": "clause", "offset": [3224, 3246]}, {"key": "total-amounts", "type": "clause", "offset": [3283, 3296]}, {"key": "in-the-course-of", "type": "definition", "offset": [3326, 3342]}, {"key": "except-to-the-extent", "type": "clause", "offset": [3368, 3388]}, {"key": "necessary-for", "type": "definition", "offset": [3400, 3413]}, {"key": "the-information", "type": "clause", "offset": [3437, 3452]}, {"key": "agreement-or", "type": "definition", "offset": [3513, 3525]}, {"key": "required-by-law", "type": "definition", "offset": [3543, 3558]}, {"key": "failure-by", "type": "clause", "offset": [3560, 3570]}, {"key": "to-request", "type": "clause", "offset": [3584, 3594]}, {"key": "two-years", "type": "clause", "offset": [3635, 3644]}, {"key": "acceptance-of-the", "type": "clause", "offset": [3702, 3719]}, {"key": "no-obligation-to-maintain", "type": "clause", "offset": [3772, 3797]}, {"key": "pertaining-to", "type": "definition", "offset": [3810, 3823]}, {"key": "year-period", "type": "definition", "offset": [3864, 3875]}], "hash": "5bb167fbc87fe26e5fe92e5d51b589be", "id": 8}, {"samples": [{"hash": "e4sletUnzBs", "uri": "/contracts/e4sletUnzBs#continued-development", "label": "License Agreement (Talaris Therapeutics, Inc.)", "score": 34.5468856947, "published": true}], "size": 2, "snippet": "At Pfizer\u2019s request and expense, Licensee shall continue on-going Development with respect to such Terminated Territory for a mutually agreed-upon period following termination, which period shall not be less than [*****] unless otherwise agreed to by the Parties. For avoidance of doubt, [*****].", "snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [33, 47]}, {"key": "with-respect-to", "type": "clause", "offset": [78, 93]}, {"key": "terminated-territory", "type": "definition", "offset": [99, 119]}, {"key": "mutually-agreed", "type": "clause", "offset": [126, 141]}, {"key": "following-termination", "type": "clause", "offset": [154, 175]}, {"key": "by-the-parties", "type": "clause", "offset": [248, 262]}, {"key": "for-avoidance-of-doubt", "type": "clause", "offset": [264, 286]}], "hash": "1e51e7f9c485ae9b82e31cc90972fc7e", "id": 9}, {"samples": [{"hash": "lfOyP0UVMDA", "uri": "/contracts/lfOyP0UVMDA#continued-development", "label": "Purchase and Sale Agreement (Bare Escentuals Inc)", "score": 21.0, "published": true}], "size": 1, "snippet": "From the Effective Date until the Termination Date (as defined below) (the \u201cDevelopment Period\u201d), Buyer shall use commercially reasonable efforts to develop the Pipeline Products substantially in accordance with the Pipeline Specifications. The parties shall agree in writing on a completion date (a \u201cCompletion Date\u201d) for each Pipeline Product and a development budget for each such Pipeline Product. Such development budget shall include a schedule for payment of Allergan\u2019s share of Buyer\u2019s costs, as set forth in Section 1.1(c), below, and shall provide for a hold back of *** of the budgeted costs until development of said Pipeline Product is completed to Allergan\u2019s reasonable satisfaction. Allergan understands and acknowledges that the development of any particular Pipeline Product in accordance with the Pipeline Specifications by the Completion Date may not be feasible and that Buyer may change such Pipeline Specifications or Completion Date with Allergan\u2019s written consent, which shall not be unreasonably withheld. Buyer will not be in breach of its obligations hereunder if its reasonable commercial efforts are not sufficient to successfully complete the development of any particular Pipeline Product. Allergan agrees to use reasonable commercial efforts to assist Buyer in the continued development of Pipeline Products, including but not limited to, making its marketing staff reasonably available to Buyer for up to one day during any calendar month during the Development Period.", "snippet_links": [{"key": "from-the-effective-date", "type": "clause", "offset": [0, 23]}, {"key": "termination-date", "type": "definition", "offset": [34, 50]}, {"key": "buyer-shall", "type": "clause", "offset": [98, 109]}, {"key": "use-commercially-reasonable-efforts", "type": "clause", "offset": [110, 145]}, {"key": "to-develop", "type": "definition", "offset": [146, 156]}, {"key": "pipeline-products", "type": "clause", "offset": [161, 178]}, {"key": "in-accordance-with", "type": "definition", "offset": [193, 211]}, {"key": "the-parties-shall", "type": "clause", "offset": [241, 258]}, {"key": "in-writing", "type": "clause", "offset": [265, 275]}, {"key": "development-budget", "type": "clause", "offset": [351, 369]}, {"key": "payment-of", "type": "definition", "offset": [455, 465]}, {"key": "of-buyer", "type": "clause", "offset": [483, 491]}, {"key": "provide-for-a", "type": "definition", "offset": [550, 563]}, {"key": "hold-back", "type": "clause", "offset": [564, 573]}, {"key": "budgeted-costs", "type": "definition", "offset": [588, 602]}, {"key": "development-of", "type": "clause", "offset": [609, 623]}, {"key": "reasonable-satisfaction", "type": "clause", "offset": [673, 696]}, {"key": "the-completion-date", "type": "definition", "offset": [842, 861]}, {"key": "buyer-may-change", "type": "clause", "offset": [891, 907]}, {"key": "written-consent", "type": "definition", "offset": [972, 987]}, {"key": "buyer-will", "type": "clause", "offset": [1031, 1041]}, {"key": "breach-of", "type": "definition", "offset": [1052, 1061]}, {"key": "reasonable-commercial-efforts", "type": "definition", "offset": [1095, 1124]}, {"key": "complete-the", "type": "clause", "offset": [1160, 1172]}, {"key": "agrees-to", "type": "clause", "offset": [1230, 1239]}, {"key": "to-assist", "type": "clause", "offset": [1274, 1283]}, {"key": "not-limited", "type": "clause", "offset": [1355, 1366]}, {"key": "marketing-staff", "type": "definition", "offset": [1382, 1397]}, {"key": "to-buyer", "type": "definition", "offset": [1419, 1427]}, {"key": "calendar-month", "type": "definition", "offset": [1457, 1471]}, {"key": "during-the-development-period", "type": "clause", "offset": [1472, 1501]}], "hash": "70b5dfdde01ffe1f4279b01a2daa4fca", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ih5jb250aW51ZWQtZGV2ZWxvcG1lbnQjMDAwMDAwMGEMogECZW4YACAA", "clause": {"title": "Continued Development", "size": 39, "children": [["manufacturing-and-supply", "Manufacturing and Supply"], ["annual-volume-commitment-term", "Annual Volume Commitment Term"], ["act-a-coordination", "ACT-A Coordination"], ["insufficient-supply-to-meet-global-demand", "Insufficient Supply to Meet Global Demand"], ["termination-of-price-and-volume-commitments", "Termination of Price and Volume Commitments"]], "parents": [["term-termination", "Term Termination"], ["effects-of-termination", "Effects of Termination"], ["transition", "Transition"], ["termination-by-pfizer-for-cause-bankruptcy-event-termination-by-licensee-for-convenience", "Termination by Pfizer for Cause, Bankruptcy Event; Termination by Licensee for Convenience"], ["ownership-interest-product-development", "Ownership Interest Product Development"]], "id": "continued-development", "related": [["career-development", "Career Development", "Career Development"], ["continuing-professional-development", "Continuing Professional Development", "Continuing Professional Development"], ["research-and-development", "Research and Development", "Research and Development"], ["learning-and-development", "Learning and Development", "Learning and Development"], ["job-development", "Job Development", "Job Development"]], "related_snippets": [], "updated": "2025-07-07T12:37:50+00:00", "also_ask": ["What minimum development milestones should be mandated to ensure ongoing progress?", "How can termination rights be structured if development stalls or fails?", "What are the key risks if 'continued development' is not clearly defined or time-bound?", "How do courts interpret ambiguous 'continued development' obligations in similar agreements?", "What negotiation leverage exists around performance standards and remedies for non-compliance?"], "drafting_tip": "Specify development milestones to track progress, define parties\u2019 obligations to clarify responsibilities, and set review mechanisms to address evolving needs.", "explanation": "The Continued Development clause outlines the parties' obligations and rights regarding the ongoing improvement or enhancement of a product, service, or intellectual property after the initial delivery or launch. Typically, this clause specifies whether the developer or provider must continue to update, upgrade, or maintain the offering, and may detail the scope, duration, and compensation for such work. Its core practical function is to ensure that the subject of the agreement remains current and functional over time, addressing the need for adaptability and sustained value in long-term projects or relationships."}, "json": true, "cursor": ""}}